| Neutropenia |
2015-003940-38: Study of posaconazole blood levels comparing two different oral presentations, a syrup and a solid tablet, in patients with leukaemia at a high risk of fungal infections Estudio de niveles de posaconazol en sangre comparando dos presentaciones del fármaco, una en jarabe y otra en tabletas, en pacientes con leucemia con alto riesgo de infecciones fúngicas |
|
|
| Ongoing | 4 | 20 | Europe | Oral suspension, Gastro-resistant tablet, Noxafil 40 mg/ml suspensión oral, Noxafil 100 mg comprimidos gastrorresistentes | Fundación Investigación Biomédica Puerta de Hierro, Merck Sharp & Dohme España | Invasive Mycoses Micosis invasoras, Severe fungal infections Infecciones graves por hongos, Diseases [C] - Bacterial Infections and Mycoses [C01] | | | | |
2019-002197-31: AFAMOSI: Efficacy and safety of afatinib followed by osimertinib compared to osimertinib in patients with EGFRmutated/T790M Mutation negative non-squamous NSCLC. AFAMOSI: Wirksamkeit und Sicherheit von Afatinib gefolgt von Osimertinib verglichen mit Osimertinib bei Patienten mit EGFR-mutiertem/T790M-negativem nicht zu den Plattenepithelkarzinom-zählendem NSCLC. |
|
|
| Not yet recruiting | 4 | 126 | Europe | Film-coated tablet, Giotrif, Tagrisso | Universitätsmedizin Mainz, Interdisziplinäres Zentrum klinische Studien, Boehringer Ingelheim Pharma GmbH & Co KG | EGFR mutated non-squamous NSCLC EGFR-mutiertes nicht plattenepithelialen NSCLC, non-small cell lung Cancer (NSCLC) Nicht kleinzelliges Lungenkarzinom (NSCLC), Diseases [C] - Cancer [C04] | | | | |
2021-001257-31: A single center study comparing the safety and tolerability after separate single intra-hepatic (liver) injections of idarubicin 10 mg and 15 mg together with a lipid based formulation to patients with liver cancer. |
|
|
| Ongoing | 4 | 30 | Europe | idarubicin hydrochloride, Powder for solution for injection, Zavedos® | Department of Pharmaceutical Biosciences, Uppsala University, Cancerfonden | intermediate stage hepatocellular carcinoma, primary liver cancer, Diseases [C] - Cancer [C04] | | | | |
NCT05071703: Evaluation of TRILACICLIB in Chinese Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC) for Chemotherapy-induced Myelosuppression, Antitumor Effects of Combination Regimens, and Safety in a Real-world Study |
|
|
| Completed | 4 | 30 | RoW | Trilaciclib, Trilaciclib, carboplatin, etoposide#or Topotecan | Jiangsu Simcere Pharmaceutical Co., Ltd., G1 Therapeutics, Inc. | Extensive-stage Small-cell Lung Cancer | 04/22 | 11/22 | | |
CEF-10, NCT05061654: CEFtolozane-Tazobactam for the Empiric Anti-bacterial Treatment of Neutropenic Fever in Hematology Patients |
|
|
| Withdrawn | 4 | 164 | RoW | Ceftolozane-tazobactam IV, Zerbaxa | Hamad Medical Corporation, Merck Sharp & Dohme LLC | Neutropenia, Febrile, Hematologic Cancer | 01/24 | 06/24 | | |
| Completed | 4 | 255 | Europe, Canada, Japan, US, RoW | Data Collection | Bayer | Neoplasm Metastasis / Bone and Bones | 01/24 | 01/24 | | |
NCT04413201: AFAMOSI: Efficacy and Safety of Afatinib Followed by Osimertinib Compared to Osimertinib in Patients With EGFRmutated/T790M Mutation Negative Nonsquamous NSCLC |
|
|
| Active, not recruiting | 4 | 34 | Europe | Afatinib, Osimertinib | Michael Hopp, Boehringer Ingelheim | Non-squamous NSCLC | 06/24 | 06/24 | | |
NEUTHREE, NCT05949333: Reducing Neutropenia Incidence With Pegfilgrastim Administration on Day 3 After Chemotherapy |
|
|
| Recruiting | 4 | 100 | RoW | Eflapegrastim, Rolvedon, Eflapegrastim-xnst, HM-10460A, SPI-2012 | Eunseong Medical Foundation Good GANG-AN HOSPITAL, Hanmi Pharmaceutical Company Limited | Breast Neoplasms | 01/25 | 07/25 | | |
NCT06616571: Compare the Efficacy and Safety of QL0605 Injections at Different Timepoints |
|
|
| Recruiting | 4 | 336 | RoW | QL0605(PEG-rhG-CSF) | Qilu Pharmaceutical Co., Ltd. | Chemotherapy-Induced Febrile Neutropenia | 12/25 | 12/25 | | |
CLEMENT, NCT06342115: Ceftolozane/Tazobactam Versus Meropenem for Febrile Neutropenia on Patients Colonized With or at Risk for Infection With Extended Spectrum Beta Lactamase - Producing Pathogens |
|
|
| Not yet recruiting | 4 | 176 | RoW | Ceftolozane-Tazobactam, Meropenem | Beneficência Portuguesa de São Paulo, Merck Sharp & Dohme LLC | Febrile Neutropenia | 04/25 | 04/25 | | |
| Active, not recruiting | 4 | 31 | US | Letermovir | Tufts Medical Center, Merck Sharp & Dohme LLC | Cytomegalovirus Disease, Cytomegalovirus Infections, Heart Transplant Infection, Antiviral Toxicity, Neutropenia | 10/25 | 12/25 | | |
Guard-01, ChiCTR2300077504: Efbemalenograstim alfa for primary prophylaxis of neutropenia in patients during concurrent chemoradiotherapy: a multicenter, prospective, randomized study |
|
|
| Not yet recruiting | 4 | 120 | China | Subjects received efbemalenograstim alfa 20 mg/dose subcutaneously (SC) 48h (±4h) after receiving chemotherapy of each chemotherapy cycle.; When the neutrophil count (ANC) of the subjects < 1.0×10^9/L, rhG-CSF 5μg/kg/d was given until the ANC >= 5×10^9/L. Subjects with FN or dose-limiting neutropenia are allowed to use efbemalenograstim alfa for secondary prophylaxis. | Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Neutropenia | | | | |
2014-002386-30: Efficacy and Safety of Mistletoe Extract in the Palliative Therapy of Patients Suffering from Pancreatic Cancer (PALM-Pan) |
|
|
| Ongoing | 3 | 290 | Europe | Fermented aqueous extract of Viscum album ssp album [L.] (mistletoe), Solution for injection, Iscador® Qu | Verein für Krebsforschung, Verein für Krebsforschung | Locally advanced or metastatic adenocarcinoma of the pancreas (UICC stadium III or IV), Patients Suffering from Pancreatic Cancer, Diseases [C] - Cancer [C04] | | | | |
NCT02214381: A Prospective, Multicenter, Open-label 12 Week Neoadjuvant Phase II Trial Optimizing Taxane Therapy in Elderly Patients With Low Response |
|
|
| Active, not recruiting | 3 | 80 | Europe | Myocet, Doxorubicin, Cyclophosphamide, Paclitaxel | West German Study Group, Teva Pharmaceuticals USA | Early Primary Breast Cancer | 10/15 | 10/24 | | |
2015-000897-36: A study to compare masitinib in combination with irinotecan to placebo in combination with irinotecan in the treatment of patients with esophagogastric adenocarcinoma Κλινική μελέτη για τη σύγκριση της μασιτινίμπης σε συνδυασμό με ιρινοτεκάνη έναντι του συνδυασμού placebo με ιρινοτεκάνη στη θεραπεία ασθενών με οισοφαγογαστρικό αδενοκαρκίνωμα |
|
|
| Ongoing | 3 | 364 | Europe | Masitinib, Irinotecan, AB1010, INEOF00997, Film-coated tablet, Concentrate for solution for infusion, IRINOTECAN/DEMO | AB science, AB science | Πatients with advanced-stage esophagogastric adenocarcinoma who have relapsed after first-line chemotherapy Ασθενείς με προχωρημένου σταδίου οισοφαγογαστρικό αδενοκαρκίνωμα οι οποίοι υποτροπίασαν μετά από την πρώτης γραμμής χημειοθεραπεία, Εsophagogastric adenocarcinoma Οισοφαγογαστρικό αδενοκαρκίνωμα, Diseases [C] - Digestive System Diseases [C06] | | | | |
2009-012518-39: A phase III, open label, randomized, multicenter trial of ofatumumab maintenance treatment versus no further treatment in subjects with relapsed chronic lymphocytic leukemia (CLL) who have responded to induction therapy |
|
|
| Ongoing | 3 | 60 | Europe | OFATUMUMAB, GSK1841157, | GlaxoSmithKline Research and Development, GlaxoSmithKline Research and Development Limited, GlaxoSmithKline, GlaxoSmithKline Research & Development Limited, GlaxoSmithKline S.A, , GlaxoSMithKline, GlaxoSmithKline | Subjects who are in CR or PR after 1 or 2 treatments for relapsed CLL | | | | |
2017-000390-37: Maintaining or Stopping immunosuppressive Therapy in patients with ANCA vasculitis and End-stage Renal disease: a prospective, multicenter, randomized, open-label, clinical trial |
|
|
| Not yet recruiting | 3 | 136 | Europe | Coated tablet, Solution for injection, Tablet, Imurel 25 mg, MABTHERA 100mg, Cellcept, Cortancyl | Centre Hospitalier Départemental Vendée de la Roche sur Yon, Centre Hospitalier Départemental Vendée | End-stage renal diseaseANCA vascularitisImmunosuppressive therapy, End-stage renal diseaseANCA vascularitisImmunosuppressive therapy, Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Therapeutic techniques [E02] | | | | |
2017-001025-41: Prevention of the return of nephrotic syndrom in children by adding levamisole to the prednison treatment Voorkomen van terugval nefrotisch syndroom bij kinderen door toevoegen van levamisol aan prednisolon behandeling |
|
|
| Ongoing | 3 | 92 | Europe | Levamisole 5 mg, Levamisole 10 mg, Levamisole 25 mg, Levamisole 50 mg, Film-coated tablet | Academic Medical Center, Amsterdam University Medical Center, location AMC, Dutch Kidney Foundation, ACE Pharmaceuticals | steroid sensitive idiopathic nephrotic syndrome Steroide gevoelig idiopatisch nefrotisch syndroom, idiopatic nephrotic syndrome, Diseases [C] - Immune System Diseases [C20] | | | | |
NCT01853826 / 2009-017661-34: An Open Label Trial of Afatinib (Giotrif) in Treatment-naive (1st Line) or Chemotherapy Pre-treated Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s) |
|
|
| Completed | 3 | 481 | Europe, RoW | afatinib | Boehringer Ingelheim | Carcinoma, Non-Small-Cell Lung | 04/18 | 03/24 | | |
2018-002944-10: Trial comparing subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC) treated with Docetaxel vs. subjects treated with a combination of Docetaxel and Radium-223 |
|
|
| Not yet recruiting | 3 | 738 | Europe | Solution for injection, Xofigo | Memorial Sloan Kettering Cancer Center, Bayer Healthcare LLC | Patients with histological or cytological proof of Metastatic Castration-Resistant Prostate Cancer (mCRPC), Advanced prostate cancer with bone metastases, Diseases [C] - Cancer [C04] | | | | |
2019-002288-84: Testing the delivery of an anti-cancer drug, gemcitabine, directly into the pancreas in patients with pancreatic cancer |
|
|
| Not yet recruiting | 3 | 320 | Europe | Gemcitabine, Concentrate for solution for injection | RenovoRx, Inc., RenovoRx | Locally advanced pancreatic cancer, Pancreatic cancer, Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Therapeutic techniques [E02] | | | | |
| Active, not recruiting | 3 | 221 | RoW | Pegfilgrastim, Neulasta, G-CSF, Plinabulin, BPI-2358, NPI-2358, D5W Placebo, Docetaxel, doxorubicin, and cyclophosphamide (TAC), Taxotere, Adriamycin, Cytoxan | BeyondSpring Pharmaceuticals Inc. | Chemotherapy-induced Neutropenia | 09/20 | 09/25 | | |
|
|
|
|
|
|
|
|
|
|
2019-002962-10: An unblinded study to compare the treatment success and tolerability of a chemotherapy consisting of a combination of rituximab, ifosfamide, carboplatin and etoposide with and without the addition of polatuzumab vedotin in subject suffering from an aggressive lymphoma, a malignant disease of the lymphatic system. |
|
|
| Not yet recruiting | 3 | 334 | Europe | Polivy, Mabthera, Ifosfamide, Carboplatin, Etoposide, Powder for concentrate for solution for infusion, Concentrate for solution for infusion, Powder for solution for injection/infusion, Polivy, MABTHERA® | GWT-TUD GmbH, F. Hoffmann-La Roche Ltd | primary refractory or relapsed diffuse large B-cell lymphoma (DLBCL), patients whose cancer of the lymph nodes has returned or not responded to treatment, Diseases [C] - Blood and lymphatic diseases [C15] | | | | |
TRACES, NCT04902885: Phase 3 Study Evaluating Efficacy, Safety and Pharmacokinetics of Trilaciclib In Small Cell Lung Cancer Patients |
|
|
| Completed | 3 | 95 | RoW | Trilaciclib, carboplatin, etoposide，or Topotecan, Trilaciclib plus chemotherapy, placebo, carboplatin, etoposide，or Topotecan, placebo plus chemotherapy | Jiangsu Simcere Pharmaceutical Co., Ltd., G1 Therapeutics, Inc. | Extensive-stage Small-cell Lung Cancer | 12/21 | 12/22 | | |
|
NCT05108545: A Study of Amphotericin B Liposome for Injection in Patients With Persistent Neutropenia and Fever |
|
|
| Not yet recruiting | 3 | 93 | NA | Amphotericin B liposomes | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Neutropenia and Fever | 07/22 | 01/23 | | |
TIGeR-PaC, NCT03257033: Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC |
|
|
| Recruiting | 3 | 190 | Europe, US | Gemcitabine, Gemzar, nab-paclitaxel, Abraxane, RenovoCath | RenovoRx | Locally Advanced Pancreatic Cancer | 06/26 | 09/26 | | |
2021-002179-21: A phase 3 study to evaluate the safety and efficacy of masitinib as add-on therapy in patients with mild to moderate Alzheimer's disease treated with standard of care: cholinesterase inhibitors, memantine |
|
|
| Not yet recruiting | 3 | 600 | Europe | Masitinib, AB1010, Film-coated tablet | AB Science, ABScience, AB Science, ABScience | Alzheimer's disease, Diseases [C] - Nervous System Diseases [C10] | | | | |
| Terminated | 3 | 326 | Europe, US, RoW | Trilaciclib, G1T28, CDK 4/6 inhibitor, Placebo | G1 Therapeutics, Inc. | Colorectal Cancer Metastatic, Myelosuppression-Adult, Chemotherapeutic Toxicity | 02/23 | 03/23 | | |
|
|
MORPHO, NCT02997202 / 2016-001061-83: A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML) |
|
|
| Completed | 3 | 356 | Europe, Canada, Japan, US, RoW | gilteritinib, Placebo | Astellas Pharma Global Development, Inc., National Heart, Lung, and Blood Institute (NHLBI), Blood and Marrow Transplant Clinical Trials Network | Acute Myeloid Leukemia | 01/23 | 05/23 | | |
|
2016-001179-60: Evaluation of the safety of 2 schedules of cabazitaxel (bi-weekly versus tri-weekly) plus prednisone in elderly men (≥ 70 years) with metastatic castration-resistant prostate cancer previously treated with a docetaxel-containing regimen (CABASTY) Gerandomiseerd fase III-onderzoek in meerdere centra ter evaluatie van de veiligheid van 2 schema's cabazitaxel (tweewekelijks versus driewekelijks) plus prednison bij bejaarde mannen (≥ 70 jaar) met gemetastaseerde castratie-resistente prostaatkanker (mCRPC) die eerder behandeld werden met een docetaxelbevattend regime (CABASTY). |
|
|
| Not yet recruiting | 3 | 170 | Europe | JEVTANA, Concentrate and solvent for solution for infusion, JEVTANA | A.R.T.I.C (Association pour la Recherche de Thérapeutiques Innovantes en Cancérologie), A.R.T.I.C (Association pour la Recherche de Thérapeutiques Innovantes en Cancérologie), SANOFI AVENTIS | Metastatic castration-resistant prostate cancer (mCRPC), Metastatic castration-resistant prostate cancer, Diseases [C] - Cancer [C04] | | | | |
LEAP-006, NCT03829319 / 2018-003824-35: Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/) |
|
|
| Active, not recruiting | 3 | 761 | Europe, Canada, Japan, US, RoW | Pembrolizumab, MK-3475, Carboplatin, Cisplatin, Pemetrexed, Lenvatinib, MK-7902, E7080, Placebo matching lenvatinib | Merck Sharp & Dohme LLC, Eisai Inc. | Nonsquamous Non-small Cell Lung Cancer | 08/23 | 08/24 | | |
|
|
|
LEAP-006 China Extension, NCT04716933: Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)-China Extension Study |
|
|
| Active, not recruiting | 3 | 201 | RoW | Pembrolizumab, MK-3475, Carboplatin, Cisplatin, Pemetrexed, Lenvatinib, MK-7902, E7080, Placebo matching lenvatinib | Merck Sharp & Dohme LLC, Eisai Inc. | Nonsquamous Non-small Cell Lung Cancer | 08/23 | 08/24 | | |
NCT06254742: A Trial of HHPG-19K Injection and Auto-HHPG-19K Injection in Prevention of Chemotherapy-related Moderate to Severe Neutropenia of Patients With Nonmyeloid Malignancies |
|
|
| Not yet recruiting | 3 | 107 | RoW | HHPG-19K Injection | Jiangsu HengRui Medicine Co., Ltd. | Patients With Nonmyeloid Malignancies Receiving Antineoplastic Therapy Based on Chemotherapy Regimens at Moderate to High Febrile Neutropenia (FN) Risk | 05/24 | 06/24 | | |
NCT05790096: Effectiveness and Safety Study of Filgrastine® in Patientes With Breast Cancer Treated With Myelotoxic Chemotherapy |
|
|
| Not yet recruiting | 3 | 60 | NA | Granulokine, Filgrastine | Blau Farmaceutica S.A. | Breast Cancer | 06/24 | 12/24 | | |
| Active, not recruiting | 3 | 252 | Europe, US, RoW | Obinutuzumab, Gazyva, GA101, RO5072759, MMF, Prednisone, Placebo, Methylprednisolone, Acetaminophen, Diphenhydramine | Hoffmann-La Roche | Lupus Nephritis | 08/24 | 02/29 | | |
|
Pola-R-ICE, NCT04833114: Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide () Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL) |
|
|
| Recruiting | 3 | 334 | Europe | Polatuzumab Vedotin, Mabthera, Ifosfamide, Carboplatin, Etoposide | GWT-TUD GmbH, Hoffmann-La Roche | Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | 10/24 | 12/25 | | |
| Recruiting | 3 | 740 | Europe | R1: Ixazomib, Lenalidomide, Dexamethasone (IRD) induction therapy - reactive arm, Ninlaro, Revlimid, R1: Ixazomib, Lenalidomide, Dexamethasone (IRD) induction therapy - adaptive arm, R2: Lenalidomide plus placebo maintenance, R2: Lenalidomide + ixazomib maintenance | University of Leeds, Cancer Research UK, Takeda, Celgene | Multiple Myeloma | 12/24 | 12/24 | | |
NCT06056297: A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections |
|
|
| Recruiting | 3 | 150 | Europe, RoW | Mavorixafor, X4P-001, Placebo | X4 Pharmaceuticals | Neutropenia | 07/26 | 08/26 | | |
ARASAFE, NCT05676203: A Trial Comparing Docetaxel 75 mg/m2 (3w) Versus Docetaxel 50 mg/m2 (2w) in Combination With Darolutamide + ADT in mHSPC Patients |
|
|
| Recruiting | 3 | 250 | Europe | Standard ADT (androgen deprivation therapy), Standard Darolutamide, Docetaxel | Jena University Hospital, Bayer | Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) | 02/25 | 08/26 | | |
E-CELERATE, NCT05181540: A Study of the Effects of AB-205 in Patients With Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation |
|
|
| Terminated | 3 | 130 | US | AB-205, E-CEL cells, Placebo | Angiocrine Bioscience, California Institute for Regenerative Medicine (CIRM) | Hodgkin Lymphoma, Non Hodgkin Lymphoma | 12/23 | 01/24 | | |
LEAP-014, NCT04949256 / 2020-001911-26: Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/) |
|
|
| Recruiting | 3 | 862 | Europe, Canada, Japan, US, RoW | Pembrolizumab, MK-3475, KEYTRUDA®, Lenvatinib, MK-7902, E7080, LENVIMA®, Cisplatin, PLATINOL®, 5-FU, ADRUCIL®, Oxaliplatin, ELOXATIN®, Leucovorin, calcium folinate, folinic acid, WELLCOVORIN®, Levoleucovorin, calcium levofolinate, levofolinic acid, FUSILEV®, Paclitaxel, TAXOL®, ONXAL® | Merck Sharp & Dohme LLC, Eisai Inc. | Metastatic Esophageal Squamous Cell Carcinoma | 12/25 | 12/25 | | |
|
LEAP-015, NCT04662710 / 2020-001990-53: Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/) |
|
|
| Active, not recruiting | 3 | 890 | Europe, Canada, Japan, US, RoW | Pembrolizumab, MK-3475, Keytruda®, Lenvatinib, MK-7902, E7080, Oxaliplatin, Capecitabine, Leucovorin (or Levoleucovorin), 5-FU | Merck Sharp & Dohme LLC, Eisai Inc. | Advanced/Metastatic Gastroesophageal Adenocarcinoma | 02/26 | 02/26 | | |
VERITAC-3, NCT05909397: A Study of ARV-471 (PF-07850327) Plus Palbociclib Versus Letrozole Plus Palbociclib in Participants With Estrogen Receptor Positive, Human Epidermal Growth Factor Negative Advanced Breast Cancer |
|
|
| Active, not recruiting | 3 | 1180 | Europe, Japan, US, RoW | ARV-471 (PF-07850327), Vepdegestrant, Palbociclib, IBRANCE®, Letrozole, FEMARA® | Pfizer, Arvinas Estrogen Receptor, Inc. | Breast Cancer | 08/28 | 07/30 | | |
2011-001462-17: Trial for the optimisation of risk assessment and therapy success predicition in patients with early breast cancer by the use of biomarkers in advance to therapy decission-making to personalize therapies. |
|
|
| Ongoing | 2/3 | 5236 | Europe | Epirubicin, Cyclophosphamide, Paclitaxel, Tamoxifen, Anastrozole, Letrozole, Exemestan, trastuzumab emtansine (T-DM1), Trastuzumab, Paclitaxel-Albumin, Gemcitabine, Carboplatin, Pertuzumab, Myocet, RO530-4020/xxx, RO4368451, Concentrate for solution for infusion, Tablet, Powder for concentrate for solution for infusion, Powder for solution for infusion, Kadcyla, Herceptin 150 mg, Abraxane, Perjeta | Westdeutsche Studiengruppe GmbH, Genomic Health , Inc., Roche Pharma AG, Celgene Corp., Amgen, TEVA GmbH, Bayer AG | Early primary breast cancer, hormone receptor positve or negative, HER2 positive or negative, any nodal status., Early diagnosed breast cancer at first occurence, with hormone receptor over-expressing tumor and any lymph node involvement (from none to any)., Diseases [C] - Cancer [C04] | | | | |
2010-021091-28: A clinical study to determine whether a new drug masitinib is safe and effective in cancer of the white blood cells. |
|
|
| Ongoing | 2/3 | 267 | Europe, RoW | Masitinib mesylate, Gemcitabine, Dexamethasone, AB1010, Film-coated tablet, Powder for infusion, Tablet, Gemcitabine, Dexamethasone | AB Science, AB Science | Relapsed or refractory peripheral T-cell lymphoma, Cancer of the white blood cells (T-lymphocytes), Diseases [C] - Cancer [C04] | | | | |
2012-004222-25: Comparison of efficacy of masitinib versus placebo in the treatment of Crohn's disease |
|
|
| Ongoing | 2/3 | 450 | Europe | Masitinib, AB1010, Film-coated tablet | AB Science, AB Science | Crohn's disease, Inflammatory bowel disease, Diseases [C] - Digestive System Diseases [C06] | | | | |
2020-001167-93: A clinical trial investigating efficacy and safety of emapalumab and anakinra in patients with Coronavirus disease (COVID-19) Studio clinico per valutare l'efficacia e la sicurezza di emapalumab e anakinra in pazienti con COVID-19 |
|
|
| Not yet recruiting | 2/3 | 54 | Europe | Kineret, Emapalumab, [Kineret], [Emapalumab], Solution for injection, KINERET - "100 MG/0,67 ML SOLUZIONE INIETTABILE" USO SOTTOCUTANEO SIRINGA PRERIEMPITA 7 SIRINGHE PRERIEMPITE, Gamifant | SWEDISH ORPHAN BIOVITRUM AB (PUBL), Swedish Orphan Biovitrum AB (publ) | SARS-CoV-2 infection Infezione da SARS-CoV-2, Coronavirus disease (COVID-19) Malattia da Coronavirus (COVID-19), Diseases [C] - Virus Diseases [C02] | | | | |
2019-001258-25: A phase II and phase III trial comparing treatment escalation and de-escalation strategies in newly diagnosed patients with multiple myeloma suitable for stem cell transplant (TE) |
|
|
| Ongoing | 2/3 | 1400 | Europe | Isatuximab, Revlimid (Lenalidomide), Cyclophosphamide, Dexamethasone, Bortezomib, L04AX04, Solvent for solution for infusion, Capsule, hard, Tablet, Solution for injection, Kyprolis, Revlimid (Lenalidomide), Cyclophosphamide, Dexamethasone, Bortezomib | University of Leeds, Cancer Research UK, Sanofi S.A, Celgene Corporation | Newly diagnosed multiple myeloma, Multiple myeloma, Diseases [C] - Cancer [C04] | | | | |
2021-002864-36: A phase IIb placebo-controlled efficacy and safety study of mocravimod in AML patients undergoing HSCT |
|
|
| Not yet recruiting | 2/3 | 249 | Europe | mocravimod, KRP203, 1.0 mg, Capsule, hard | Priothera S.A.S., Priothera SAS, Priothera S.A.S. | Patients undergoing allogeneic hematopoietic stem cell transplant (HSCT) for acute myeloid leukemia (AML), Patients undergoing allogeneic hematopoietic stem cell transplant (HSCT) for acute myeloid leukemia (AML), Diseases [C] - Immune System Diseases [C20] | | | | |
NCT04256317: A Study of ASTX030 (Cedazuridine in Combination With Azacitidine) in MDS, CMML, or AML |
|
|
| Recruiting | 2/3 | 317 | Canada, US | Azacitidine, Vidaza, ASTX030 (cedazuridine + azacitidine), Cedazuridine | Taiho Oncology, Inc. | Myelodysplastic Syndromes, Chronic Myelocytic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome/Neoplasm | 12/25 | 04/26 | | |
2015-000087-34: Clinical trial comparing Lipegfilgrastim to Filgrastim in Pediatric Patients Diagnosed with Ewing Family of Tumors or Rhabdomyosarcoma Receiving Chemotherapy. Vizsgálat a lipegfilgrastim kezelés összehasonlítására a filgrastim kezeléssel, Ewing tumorok családjába tartozó betegséggel, vagy rhabdomioszarkómával diagnosztizált és kemoterápiával kezelt gyermek betegekben |
|
|
| Ongoing | 2 | 42 | Europe, RoW | Lipegfilgrastim, Neupogen, XM22, Solution for injection, LONQUEX, Neupogen 30 MU (0.3 mg/ml) solution for injection | Merckle GmbH, Merckle GmbH | Neutropenia in pediatric patients diagnosed with Ewing family of Tumors or rhabdomyosarcoma receiving chemotherapy Neutropénia Ewing tumorok családjába tartozó betegséggel, vagy rhabdomioszarkómával diagnosztizált és kemoterápiával kezelt gyermek betegekben, treatment of chemotherapy induced neutropenia (white blood cell decrease) a kemoterápia okozta neutropenia (a fehérvérsejtek csökkenése), Diseases [C] - Blood and lymphatic diseases [C15] | | | | |
NCT01361711: Alemtuzumab-Ofatumumab in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia |
|
|
| Active, not recruiting | 2 | 53 | Europe, US | alemtuzumab, anti-CD52 monoclonal antibody, Campath-1H, MoAb CD52, Monoclonal Antibody Campath-1H, Monoclonal Antibody CD52, ofatumumab, Arzerra, HuMax-CD20, biopsy, biopsies | Northwestern University, GlaxoSmithKline, National Comprehensive Cancer Network | Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia, Stage IV Chronic Lymphocytic Leukemia | 08/15 | 05/27 | | |
2014-003860-19: Study comparing oral Vinorelbine administered with two different schedules in patients with Advanced Breast Cancer. |
|
|
| Ongoing | 2 | 160 | Europe | Capsule, soft, Navelbine 20mg soft capsules, Navelbine 30mg soft capsules | PIERRE FABRE MEDICAMENT, Pierre Fabre Medicament | Advanced Breast Cancer, Breast Cancer, Diseases [C] - Cancer [C04] | | | | |
2010-020603-79: Evaluation of masitinib in acute ischemic stroke Evaluación de masitinib en pacientes con ictus isquémico agudo |
|
|
| Ongoing | 2 | 45 | Europe | masitinib, AB1010 tablets, | AB Science, ABScience | patients suffering from Acute Ischemic Stroke Pacientes con ictus isquémico agudo | | | | |
2012-005586-13: A prospective, multicentre, randomised, double-blind, placebo-controlled, phase 2a study to compare the efficacy and the safety of 24-week treatment with masitinib versus placebo in patients with severe Chronic Obstructive Pulmonary Disease (COPD) Estudio de fase IIa prospectivo, multicéntrico, randomizado, doble ciego, y controlado con placebo para comparar la eficacia y seguridad del tratamiento con masitinib durante de 24 semanas frente a placebo en pacientes con Enfermedad Pulmonar Obstructiva Crónica (EPOC) |
|
|
| Ongoing | 2 | 30 | Europe | MASITINIB, AB1010, | AB SCIENCE, AB Science, AB SCIENCE, AB Science | Patients with severe COPD Pacientes con EPOC grave | | | | |
2015-002855-85: A randomized study to assess the tolerability and efficacy of the addition of ibrutinib to 10-day decitabine treatment in patients with AML and high risk myelodysplasia (MDS), UNFIT for intensive chemotherapy, aged >= 66 years. |
|
|
| Ongoing | 2 | 170 | Europe | Decitabine, ibrutinib, Powder for concentrate for solution for infusion, Capsule, soft, Dacogen, Imbruvica | HOVON Foundation, Dutch Cancer Society, Janssen-Cilag International NV | Acute Meyloid Leukemia and High Risk Myelodysplastic syndromes, Acute Meyloid Leukemia and High Risk Myelodysplastic syndromes, Diseases [C] - Cancer [C04] | | | | |
2014-005364-14: The role of Afatinib to come to radical surgery in patients with non-squamous lung cancer with EGFR gene mutation. Il ruolo di Afatinib per giungere alla chirurgia radicale in pazienti con tumore polmonare non squamoso con mutazione del gene EGFR |
|
|
| Ongoing | 2 | 46 | Europe | GIOTRIF 40 MG, GIOTRIF 20 MG, GIOTRIF 30 MG, [GIOTRIF 40 MG], [GIOTRIF 20 MG], [GIOTRIF 30 MG], Coated tablet, GIOTRIF - 40 MG - COMPRESSA RIVESTITA CON FILM - BLISTER DIVISIBILE (PVC/PVDC) 28X1 COMPRESSE, GIOTRIF - 20 MG - COMPRESSA RIVESTITA CON FILM - BLISTER DIVISIBILE (PVC/PVDC) 28X1 COMPRESSE, GIOTRIF - 30 MG - COMPRESSA RIVESTITA CON FILM - BLISTER DIVISIBILE (PVC/PVDC) 28X1 COMPRESSE | ISTITUTO EUROPEO DI ONCOLOGIA, Boehringer Ingelheim | Patients with stage IIIA or stage IIIB N2 requiring neoadjuvant treatment for pN2 non squamous non small cell lung cancer (NSCLC) with EGFR-activating mutations Pazienti con tumore polmonare non a piccole cellule (NSCLC) di tipo non squamoso stadio IIIA o stadio IIIB N2 che richiede un trattamento neoadiuvante pN2 con mutazione attivante del gene EGFR., Patients with non-squamous lung cancer with EGFR gene mutation. Pazienti con tumore polmonare non squamoso con mutazione del gene EGFR, Diseases [C] - Cancer [C04] | | | | |
2015-004985-27: A prospective, open-label, multicenter randomized phase-II trial to evaluate the efficacy and safety of a sequential regimen of obinutuzumab (Gazyvaro) followed by obinutuzumab and venetoclax, followed by either standard venetoclax maintenance or MRD guided venetoclax maintenance in first-line patients with CLL and unfit for FCR-like regimens |
|
|
| Ongoing | 2 | 70 | Europe | obinutuzumab, venetoclax 10 mg, venetoclax 50mg, venetoclax 100mg, Concentrate for solution for infusion, Tablet, Gazyvaro | HOVON Foundation, Dutch Cancer Society, Roche | Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Diseases [C] - Cancer [C04] | | | | |
NCT02244125 / 2013-001432-22: A Multicenter Open Label Phase II Study of Pomalidomide and Cyclophosphamide and Dexamethasone in Relapse/Refractory Multiple Myeloma Patients Who Were First Treated Within the IFM/DFCI 2009 Trial |
|
|
| Completed | 2 | 100 | Europe | PCD, Pomalidomide-Cyclophosphamide-Dexamethasone association, Autologous transplantation (ASCT) | Institut Curie, Intergroupe Francophone du Myelome, Celgene Corporation | Multiple Myeloma, First Relapse | 01/17 | 05/23 | | |
2016-004539-18: Study of the efficacy, safety, tolerability and drug blood levlrs of ANF-RHO to treat patients with low white blood cells count portant sur l’efficacité, la sécurité d’emploi, la tolérabilité et la pharmacocinétique d’ANF–Rho™ chez les patients souffrant d'une baisse de nombre de globules blanches. |
|
|
| Ongoing | 2 | 10 | Europe | ANF RhoTM (pegfilgrastim ANF), ANF RhoTM, Solution for injection | Prolong Pharmaceuticals, LLC, Prolong Pharmaceuticals, LLC | Chronic neutropenia Neutropénie chronique, chronic decrease of white blood cells Baisse chronique des globules blanches, Diseases [C] - Blood and lymphatic diseases [C15] | | | | |
| Completed | 2 | 126 | Europe, US, RoW | Mycophenolate Mofetil/Mycophenolic Acid, Obinutuzumab, Gazyva, GA101, RO5072759, Placebo, Methylprednisolone, Prednisone | Hoffmann-La Roche | Lupus Nephritis | 01/19 | 08/23 | | |
|
|
|
|
| Not yet recruiting | 2 | 125 | Europe | tesetaxel, Xeloda, DJ-927, Capsule, hard, Film-coated tablet, Xeloda | Odonate Therapeutics, Inc., Odonate Therapeutics, Inc. | breast cancer cáncer de mama, breast cancer cáncer de mama, Diseases [C] - Cancer [C04] | | | | |
2018-002565-18: A trial to evaluate the Safety and Efficacy of SCY-078 when co-administrated with Voriconazole to treat Patients with Invasive Aspergillosis. |
|
|
| Not yet recruiting | 2 | 60 | Europe | Ibrexafungerp, SCY-078 citrate salt, Tablet | SCYNEXIS, Inc., SCYNEXIS, Inc. | Patients with Invasive Pulmonary Aspergillosis, Infection caused by Aspergillus, a common mold (a type of fungus), Diseases [C] - Bacterial Infections and Mycoses [C01] | | | | |
2018-001344-57: Penataglobin profilaxis in patients with acute leukemia or candidate to allogeneic transplant colonized by carbapenem-resistant Enterobacteriaceae or Pseudomonas aeruginosa Profilassi con Pentaglobin nelle leucemie acute o pazienti candidati a trapianto allogenico e colonizzati da Enterobatteri resistenti ai carbapenemici o da Pseudomonas aeruginosa |
|
|
| Not yet recruiting | 2 | 120 | Europe | Pentaglobin, [Pentaglobin], Solution for infusion, PENTAGLOBIN - 50 MG/ML SOLUZIONE PER INFUSIONE 1 FLACONCINO DA 10 ML, PENTAGLOBIN - 50 MG/ML SOLUZIONE PER INFUSIONE 1 FLACONE DA 50 ML, PENTAGLOBIN - 50 MG/ML SOLUZIONE PER IINFUSIONE 1 FLACONE DA 100 ML | GITMO GRUPPO ITALIANO PER IL TRAPIANTO DI MIDOLLO OSSEO, CELLULE STAMINALI EMOPOIETICHE E TERAPIA, Biotest AG | The study will enroll consecutive adult patients suffering from acute leukemia candidate to intensive chemotherapy or patients with hematological cancers candidate to allogeneic transplant with a documented colonization sustained by Carbapenem-resistant Enterobacteriaceae or Pseudomonas aeruginosa. Pazienti adulti affetti da leucemia acuta e candidati a chemioterapia intensiva o pazienti con malattie ematologiche con indicazione a trapianto allogenico con documentata una colonizzazione da Enterobatteriaceae resistenti ai carbapenemi o da Pseudomonas aeruginosa., Patients with acute leukemia or candidate to allogeneic transplant for hematological disease with Gram-negative infection antibiotic-resistant Pazienti con leucemia acuta o pazienti candidati al trapianto di midollo per malattia ematologica portatori di germi Gram-negativi resistenti agli antibiotici, Diseases [C] - Blood and lymphatic diseases [C15] | | | | |
| Active, not recruiting | 2 | 281 | Europe | Autologous Stem Cell Transplant (ASCT), Consolidation with 4 cycles of CarCyDex | University College, London, Amgen | Multiple Myeloma | 11/19 | 11/29 | | |
NCT02768792: High Dose Cytarabine Followed by Pembrolizumab in Relapsed/Refractory AML |
|
|
| Completed | 2 | 38 | US | pembrolizumab,, KEYTRUDA, MK-3475 | UNC Lineberger Comprehensive Cancer Center, Merck Sharp & Dohme LLC | Acute Myeloid Leukemia, in Relapse | 11/19 | 06/24 | | |
NCT03623373: Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma |
|
|
| Active, not recruiting | 2 | 13 | US | Bendamustine, Treanda, Bendeka, Rituximab, Rituxan, Rituxan Hycela, Acalabrutinib, Calquence®, Cytarabine, Cytosar-U, Leukapheresis, Peripheral blood, Oral rinse, Bone marrow collection | Washington University School of Medicine, Acerta Pharma BV | Mantle Cell Lymphoma | 02/20 | 02/25 | | |
NCT03007979: Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer |
|
|
| Completed | 2 | 55 | US | Palbociclib, Ibrance, Letrozole, Femara, Fulvestrant, Faslodex, Optional research biopsy, Goserelin, Zoladex, Research blood draw, Circulating tumor cell blood draw, Tumor biopsy (optional) | Washington University School of Medicine, Pfizer | Breast Cancer, Breast Carcinoma, Cancer of Breast, Malignant Tumor of Breast | 03/20 | 03/23 | | |
2018-000187-28: Efficacy of pembrolizumab in patients with marginal zone lymphoma |
|
|
| Not yet recruiting | 2 | 56 | Europe | Pembrolizumab, MK-3475, Solution for infusion, Concentrate for solution for infusion, KEYTRUDA (pembrolizumab, MK3475), Truxima | University Hospital Ulm, Universitätsklinikum Ulm, MSD SHARP & DOHME GMBH, Celltrion Healthcare Co., LTD | Marginal Zone Lymphoma, Marginal Zone Lymphoma, Diseases [C] - Cancer [C04] | | | | |
2020-001748-24: A multi-center, randomized, open-label study in patients with COVID-19 and respiratory distress not requiring mechanical ventilation, to compare standard-of-care with anakinra and tocilizumab treatment.The Immunomodulation-CoV Assessment (ImmCoVA) study. |
|
|
| Not yet recruiting | 2 | 120 | Europe | Kineret, RoActemra, Solution for injection in pre-filled syringe, Concentrate for solution for infusion, Kineret, RoActemra | Karolinska University Hospital, Karolinska University Hospital, ME Infection diseases | COVID-19 infection in patients with respiratory distress., COVID-19 infection in patients with respiratory distress., Diseases [C] - Virus Diseases [C02] | | | | |
GOSSAMER, NCT02927262 / 2016-001643-39: A Study of ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete Remission |
|
|
| Completed | 2 | 98 | Europe, Canada, Japan, US, RoW | Gilteritinib, ASP2215, Placebo | Astellas Pharma Global Development, Inc. | Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) / Internal Tandem Duplication (ITD) Mutation | 05/21 | 02/24 | | |
2021-001813-35: AGORA-1 / ALFA 2100 STUDY:PHASE 2 ON THE COMBINATION OF GEMTUZUMAB OZOGAMICIN WITH GILTERITINIB IN ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) WITH FLT3 MUTATION TO RELAPSE OR REFRACTORY ETUDE AGORA-1 / ALFA 2100 :PHASE 2 SUR LA COMBINAISON DU GEMTUZUMAB OZOGAMICINE AVEC LE GILTERITINIB CHEZ LES PATIENTS ADULTES ATTEINTS DE LEUCEMIE AIGÜE MYELOÏDE (LAM) AVEC MUTATION FLT3 EN RECHUTE OU REFRACTAIRE |
|
|
| Not yet recruiting | 2 | 50 | Europe | Gemtuzumab ozogamicine, Gilteritinib, NA, ASP2215, Powder for solution for infusion, Film-coated tablet, Mylotarg®, Xospata® | Centre Antoine Lacassagne, Phizer Europe, Astellas Pharma Europe Ltd | Adult patients (aged 18 years old or more) with a newly diagnosis of relapsed/refractory (R/R) AML associated to the presence a FLT3 gene internal tandem duplication (FLT3-ITD). Patients adultes (âgés de 18 ans ou plus) avec un nouveau diagnostic de LAM en rechute/réfractaire (R/R) associée à la présence d'une duplication interne en tandem du gène FLT3 (FLT3-ITD)., Refractory acute myeloid leukemia (AML) or which reappears after a phase of remission (relapse), with an FLT3 mutation responsible for the development and survival of leukemia cells. Leucémie aigüe myéloïde (LAM) réfractaire ou qui réapparait après une phase de rémission (rechute), avec une mutation FLT3 responsable du développement et la survie des cellules leucémiques., Diseases [C] - Cancer [C04] | | | | |
| Active, not recruiting | 2 | 164 | Europe, Canada, US | Pevonedistat, TAK-924, MLN4924, Venetoclax, Azacitidine | Takeda | Acute Myeloid Leukemia (AML) | 09/22 | 09/24 | | |
2021-005406-96: A 24-week study to compare efficacy and safety of oral masitinib to placebo in the treatment of patients with severe mast cell activation syndrome (MCAS) with handicap unresponsive to optimal symptomatic treatment |
|
|
| Ongoing | 2 | 78 | Europe | AB1010 Tablets, AB1010 Tablets, Film-coated tablet | AB Science, AB Science | severe mast cell activation syndrome (MCAS) with handicap unresponsive to optimal symptomatic treatment, severe mast cell activation syndrome (MCAS), Diseases [C] - Blood and lymphatic diseases [C15] | | | | |
| Active, not recruiting | 2 | 255 | Europe, US, RoW | brentuximab vedotin, Adcetris, SGN-35, doxorubicin, vinblastine, dacarbazine, G-CSF, filgrastim, pegfilgrastim, nivolumab, Opdivo | Seagen Inc., Bristol-Myers Squibb | Hodgkin Lymphoma | 11/22 | 06/26 | | |
|
2022-001397-61: Clinical trial phase II with Sacituzumab govitecan in Patients with Metastatic Triple-Negative Breast Cancer Ensayo clínico fase II con Sacituzumab govitecan para pacientes con cancer de mama triple negativo |
|
|
| Not yet recruiting | 2 | 50 | Europe | Trodelvy, EU/1/21/1592/001, Powder for concentrate for solution for infusion | Medica Scientia Innovation Research SL., Gilead Sciencies SLU | Advanced triple-negative breast cancer Cáncer de mama triple negativo avanzado, Advanced triple-negative breast cancer (TNBC) Cáncer de mama triple negativo avanzado (TNBC), Diseases [C] - Cancer [C04] | | | | |
NCT04874506: MBM-02 (Tempol) for the Treatment of Glioblastoma Multiforme (GBM) |
|
|
| Not yet recruiting | 2 | 55 | US | MBM-02, Tempol; 4-hydroxy-tempo; 4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl | Matrix Biomed, Inc., MedStar Georgetown | Glioblastoma, Glioblastoma Multiforme | 01/23 | 08/23 | | |
SCYNERGIA, NCT03672292: Evaluate Safety and Efficacy of the Coadministration of Ibrexafungerp With Voriconazole in Patients With Invasive Pulmonary Aspergillosis |
|
|
| Terminated | 2 | 22 | Europe, Canada, US, RoW | SCY-078, Ibrexafungerp, Voriconazole, Oral Placebo Tablets, SCY-078 matching Placebo | Scynexis, Inc. | Invasive Pulmonary Aspergillosis | 03/23 | 03/23 | | |
2022-002579-12: First-line combination of Bcl-2 inhibitor and monoclonal antibody followed by administration of Bcl-2 inhibitor alone or combination of Bcl-2 inhibitor with BTK inhibitor according to disease status of the young patient with high risk Chronic Lymphatic Leukemia Associazione di un inibitore di Bcl-2 e un anticorpo monoclonale in prima linea seguita dalla somministrazione del solo inibitore di Bcl-2 o dall'associazione dell'inibitore di Bcl-2 con un inibitore di BTK in base all'andamento della malattia del paziente giovane con Leucemia linfatica cronica ad alto rischio. |
|
|
| Not yet recruiting | 2 | 78 | Europe | Gazyvaro 1000 mg, Venclyxto 10 mg, Venclyxto 50 mg, Venclyxto 100 mg, Brukinsa, Bactrim, Lamivudina, Trimeton, Tachipirina, Decadron, Allopurinolo, [NA], [N.A.], Concentrate for solution for infusion, Film-coated tablet, Capsule, hard, Tablet, Concentrate for solution for injection, Solution for injection, Buccal tablet | FONDAZIONE GIMEMA (GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL' ADULTO) FRANCO MANDELLI ONLUS, BeiGene, Roche, Fondazione GIMEMA Franco Mandelli Onlus | Chronic Lymphocytic Leukemia Leucemia linfatica cronica, Form of cancer characterized by the abnormal proliferation of a particular type of cells present in the blood (lymphocytes) with consequent accumulation in various parts of the body Forma di cancro caratterizzata dalla proliferazione abnorme di un particolare tipo di cellule presenti nel sangue (linfociti) con conseguente accumulo in varie parti del corpo, Diseases [C] - Blood and lymphatic diseases [C15] | | | | |
| Terminated | 2 | 92 | Europe, US, RoW | Trilaciclib, Cosela, G1T28, Gemcitabine, Cisplatin, Carboplatin, Avelumab, Bavencio | G1 Therapeutics, Inc. | Urothelial Carcinoma, Bladder Cancer, Myelosuppression Adult, Chemotherapy-induced Neutropenia, Metastatic Bladder Cancer | 04/23 | 03/24 | | |
|
|
|
ASTX727-10, NCT05835011: A Study of Oral Decitabine/Cedazuridine in Combination With Magrolimab in Participants With Intermediate- to Very High-Risk Myelodysplastic Syndromes (MDS) |
|
|
| Terminated | 2 | 100 | US | Decitabine/Cedazuridine, ASTX727, INQOVI, Magrolimab, Hu5F9-G4 | Astex Pharmaceuticals, Inc. | Myelodysplastic Syndromes | 08/23 | 08/23 | | |
NCT03977467: Atezolizumab and Tiragolumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor |
|
|
| Completed | 2 | 46 | US | Atezolizumab, TECENTRIQ, Chemotherapy (Arm A Only), Tiragolumab | SCRI Development Innovations, LLC, Genentech, Inc. | Non-Small Cell Lung Cancer, Solid Tumor | 08/24 | 08/24 | | |
NCT05463601: Mecapegfilgrastim for the Prevention of Dalpiciclib -Induced Neutropenia in Advanced Breast Cancer |
|
|
| Recruiting | 2 | 132 | RoW | Mecapegfilgrastim, dalpiciclib, exemestane, fulvestrant, letrozole, tamoxifen | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Jiangsu HengRui Medicine Co., Ltd. | Metastatic Breast Cancer | 12/23 | 12/24 | | |
ULTIMA, NCT04611724: A Multicenter Prospective Phase II Study of Modified FOLFIRINOX for 1st Line Treatment for Advanced Urachus Cancer |
|
|
| Recruiting | 2 | 35 | RoW | FOLFIRINOX | Asan Medical Center, Green Cross Corporation, Boryung Pharmaceutical Co., Ltd | Urachal Cancer | 12/23 | 09/24 | | |
NCT06143735: A Study of Efbemalenograstim Alfa Injection for Stage IIIB or IV NSCLC Recieving Moderate-risk Febrile Neutropenia (FN) Chemotherapy Regimen With Risk Factors |
|
|
| Not yet recruiting | 2 | 99 | RoW | Efgbemalenograstim alfa | Tianjin Medical University Cancer Institute and Hospital, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Non Small Cell Lung Cancer | 12/24 | 06/26 | | |
NCT04983901: PHASE II SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, PROSPECTIVE, STUDY TO DETERMINE THE IMPACT OF SERIAL PROCALCITONIN |
|
|
| Completed | 2 | 100 | US | Imipenem/Cilastatin/Relebactam, RECARBRIO™, Cefepime, Meropenem, Meropenem Trihydrate, Merrem I.V., SM-7338, Piperacillin-Tazobactam, PIPER/TAZO, Piperacillin/Tazobactam, Zosyn, Vancomycin, Daptomycin, Cubicin, LY146032, Linezolid, Zyvox | M.D. Anderson Cancer Center, Merck Sharp & Dohme LLC | Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm | 10/23 | 10/23 | | |
| Recruiting | 2 | 90 | Europe | Trastuzumab + Paclitaxel, Pegfilgrastim, Neulasta | Centre Leon Berard, Amgen | HER2-positive Breast Cancer, Operable Breast Cancer | 01/25 | 09/25 | | |
NCT06251947: Efbemalenograstim Alfa Injection for Ovarian or Cervical Cancer Receiving Chemotherapy Regimen |
|
|
| Recruiting | 2 | 83 | RoW | Efbemalenograstim Alfa | Shandong University, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Ovarian Cancer, Cervical Cancer | 06/26 | 12/26 | | |
NCT06370416: the Prevention of Bone Marrow Suppression Caused by Chemotherapy in Advanced NSCLC With Trilaciclib |
|
|
| Not yet recruiting | 2 | 40 | RoW | Trilaciclib, Trilaciclib Injection | Henan Cancer Hospital, Jiangsu Simcere Pharmaceutical Co., Ltd. | Non-small Cell Lung Cancer | 04/25 | 12/25 | | |
| Active, not recruiting | 2 | 56 | Europe | Obinutuzumab, GA101 | Christian Buske, University of Ulm, Optimapharm, Zentrum für Klinische Studien Ulm, X-act Cologne Clinical Research GmbH, Roche Pharma AG | Marginal Zone Lymphoma | 06/24 | 11/28 | | |
| Active, not recruiting | 2 | 36 | Europe | Copanlisib, Aliqopa, Rituximab, Truxima | Christian Buske, University of Ulm, Optimapharm, X-act Cologne Clinical Research GmbH, Zentrum für Klinische Studien Ulm, Celltrion Healthcare Co., LTD, Bayer | Marginal Zone Lymphoma | 06/24 | 12/29 | | |
NCT05041426: Letermovir for CMV Prevention After Lung Transplantation |
|
|
| Recruiting | 2 | 30 | US | Letermovir, Prevymis, Valganciclovir | Fernanda P Silveira, MD, MS, Merck Sharp & Dohme LLC | Lung Transplant, CMV | 07/25 | 07/25 | | |
| Recruiting | 2 | 30 | US | Trilaciclib, Lurbinectedin | UNC Lineberger Comprehensive Cancer Center, G1 Therapeutics, Inc. | Lung Cancer, Small-cell Lung Cancer | 12/25 | 12/27 | | |
| Active, not recruiting | 2 | 128 | Europe, Canada, US, RoW | Palbociclib, Ibrance, Temozolomide, Temodar, Irinotecan, Campto, Topotecan, Hycamtin, Cyclophosphamide, Cytoxan | Pfizer, Children's Oncology Group (COG) | Ewing Sarcoma, Solid Tumors, Rhabdoid Tumor, Rhabdomyosarcoma, Neuroblastoma, Medulloblastoma, Diffuse Intrinsic Pontine Glioma | 08/24 | 10/25 | | |
2022-001459-17: A study of the effects of NUC-3373 in combination with standard anticancer drugs (NUFIRI-bev) compared with FOLFIRI-bev in patients with previously treated colorectal cancers that have spread into the surrounding tissue or to another part of the body. Estudio de los efectos del NUC3373 en combinación con fármacos anticancerosos estándar (NUFIRI-bev) comparado con FOLFIRI-bev en pacientes con cáncer colorrectal previamente tratados que se han extendido al tejido circundante o a otra parte del cuerpo. |
|
|
| Ongoing | 2 | 171 | Europe | NUC-3373 for infusion, 5-Fluorouracil, Irinotecan, Bevacizumab, Leucovorin, Levo-leucovorin, V03AF03, Concentrate for solution for infusion, Solution for infusion, Solution for injection, Irinotecan Hydrochloride 20mg/ml Concentrate for Solution for Infusion, Calcium Folinate 10mg/ml Injection, Normon calcium folinate 350 mg powder for solution for injection, Zirabev 25 mg/ml concentrate for solution for infusion, Fluorouracil 25mg/ ml Injection, Fluorouracil 50mg/ml Injection, FLUOROURACILE PFIZER 50 mg/ml, solution à diluer pour perfusion | NuCana plc, NuCana plc | Relapsed, unresectable, histologically or cytologically confirmed metastatic adenocarcinoma of colon or rectum with radiologically measurable disease. Adenocarcinoma metastásico de colon o recto recidivante, irresecable, confirmado histológica o citológicamente con enfermedad radiológicamente medible., Previously treated colorectal cancer that has spread from one part of the body to another and that cannot be removed surgically Cáncer colorrectal previamente tratado que se ha extendido de una parte del cuerpo a otra y que no puede ser extirpado quirúrgicamente., Diseases [C] - Cancer [C04] | | | | |
TESLA, NCT05638698: Tg01 Vaccine / Qs-21 Stimulon™ With Or Without Balstilimab As Maintenance Therapy Following Adjuvant Chemotherapy In Patients With Resected Pancreatic Cancer |
|
|
| Active, not recruiting | 2 | 24 | US | TG01 Vaccine, QS-21, Balstilimab | University of Kansas Medical Center, Targovax ASA | Pancreas Cancer | 12/24 | 12/25 | | |
NCT04801797: Venetoclax + Azacitidine vs. Induction Chemotherapy in AML |
|
|
| Recruiting | 2 | 172 | US | Cytarabine, Ara-C, Arabinosylcytosine, Idarubicin, Daunorubicin, Liposomal daunorubicin and cytarabine, Vyxeos, Venetoclax, Venclexta, Azacitidine, Vidaza | Massachusetts General Hospital, AbbVie | Acute Myeloid Leukemia | 01/25 | 01/26 | | |
OPTec, NCT05972135: Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma |
|
|
| Recruiting | 2 | 75 | US | Teclistamab, (TECVAYLI™), Talquetamab, TALVEY™, Tocilizumab, Actemra | SCRI Development Innovations, LLC, Janssen Research & Development, LLC | Multiple Myeloma | 01/25 | 02/25 | | |
NCT02339922: Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma |
|
|
| Active, not recruiting | 2 | 33 | US | Ixazomib Citrate, MLN-9708, MLN9708, Ninlaro, Laboratory Biomarker Analysis, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Rituxan, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, RTXM83, Rituximab Biosimilar SIBP-02 | University of Washington, Millennium Pharmaceuticals, Inc. | Chronic Lymphocytic Leukemia, Follicular Lymphoma, Lymphoplasmacytic Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Small Lymphocytic Lymphoma, Waldenstrom Macroglobulinemia | 01/25 | 01/31 | | |
NCT03824483: Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL) |
|
|
| Recruiting | 2 | 230 | US | Zanubrutinib, Obinutuzumab, GA101, Venetoclax, ABT-199 | Memorial Sloan Kettering Cancer Center, BeiGene USA, Inc., Roche-Genentech, Massachusetts General Hospital | Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Leukemia (SLL) | 02/25 | 02/25 | | |